CDH2 and adenocarcinoma: In a subsequent paper [13], PD-L1 positivity was observed only in the SCNC group (n = 16) (which were N-cadherin-positive), while other samples seemed not to express PD-L1 (30 benign prostates, 15 “low level” adenocarcinomas, 15 “high level” adenocarcinomas, 18 CRPCs).